Divi's Laboratories (DIVISLAB) Panoramica del titolo
Divi's Laboratories Limited si occupa della produzione e della vendita di ingredienti farmaceutici attivi (API), intermedi e nutraceutici generici in India, Nord America, Asia, Europa e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 0/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 4/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 4/6 |
DIVISLAB Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Divi's Laboratories Limited
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | ₹9,322.00 |
| Massimo di 52 settimane | ₹9,615.00 |
| Minimo di 52 settimane | ₹5,636.50 |
| Beta | 0.24 |
| Variazione di 1 mese | 8.40% |
| Variazione a 3 mesi | 40.43% |
| Variazione di 1 anno | 54.68% |
| Variazione a 3 anni | 144.32% |
| Variazione a 5 anni | 81.97% |
| Variazione dall'IPO | 105,681.56% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Sep 03
DIVISLAB: Board Review Of June Quarter Results Will Shape Balanced Outlook
Analysts have lifted the price target for Divi's Laboratories from ₹7,059 to ₹8,447, citing updated assumptions around revenue growth, profit margins and future P/E expectations as key supports for the higher valuation range. What’s in the News for Divi's Laboratories Divi's Laboratories has scheduled a board meeting on Aug 01, 2026.
Aggiornamento narrativa • Aug 20
DIVISLAB: Upcoming June Quarter Results Will Support Bullish Outlook
Analysts have adjusted their price target on Divi's Laboratories from about ₹8,795 to about ₹10,953, reflecting updated views on its fair value, discount rate, revenue growth and profit margin assumptions, as well as the P/E they apply to the stock. What’s in the News for Divi's Laboratories Divi's Laboratories has scheduled a Board meeting on August 1, 2026.
Aggiornamento narrativa • Aug 06
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have nudged their fair value estimate for Divi's Laboratories higher from ₹5,610 to ₹6,000, citing a slightly lower discount rate, modestly adjusted revenue growth assumptions, and a small improvement in expected profit margins and future P/E levels. What's in the News for Divi's Laboratories Board meeting scheduled on May 23, 2026, to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Articolo di analisi • Aug 04
Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
A week ago, Divi's Laboratories Limited ( NSE:DIVISLAB ) came out with a strong set of quarterly numbers that could...Aggiornamento narrativa • Jul 23
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have revised their price target for Divi's Laboratories to ₹5,610 from ₹5,333.98, citing updated assumptions for revenue growth, profit margins, and future P/E that collectively support a higher fair value estimate despite a slightly higher discount rate. What’s in the News for Divi's Laboratories A board meeting is scheduled on August 1, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.Recent updates
Aggiornamento narrativa • Sep 03
DIVISLAB: Board Review Of June Quarter Results Will Shape Balanced Outlook
Analysts have lifted the price target for Divi's Laboratories from ₹7,059 to ₹8,447, citing updated assumptions around revenue growth, profit margins and future P/E expectations as key supports for the higher valuation range. What’s in the News for Divi's Laboratories Divi's Laboratories has scheduled a board meeting on Aug 01, 2026.Aggiornamento narrativa • Aug 20
DIVISLAB: Upcoming June Quarter Results Will Support Bullish Outlook
Analysts have adjusted their price target on Divi's Laboratories from about ₹8,795 to about ₹10,953, reflecting updated views on its fair value, discount rate, revenue growth and profit margin assumptions, as well as the P/E they apply to the stock. What’s in the News for Divi's Laboratories Divi's Laboratories has scheduled a Board meeting on August 1, 2026.Aggiornamento narrativa • Aug 06
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have nudged their fair value estimate for Divi's Laboratories higher from ₹5,610 to ₹6,000, citing a slightly lower discount rate, modestly adjusted revenue growth assumptions, and a small improvement in expected profit margins and future P/E levels. What's in the News for Divi's Laboratories Board meeting scheduled on May 23, 2026, to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Articolo di analisi • Aug 04
Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
A week ago, Divi's Laboratories Limited ( NSE:DIVISLAB ) came out with a strong set of quarterly numbers that could...Aggiornamento narrativa • Jul 23
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have revised their price target for Divi's Laboratories to ₹5,610 from ₹5,333.98, citing updated assumptions for revenue growth, profit margins, and future P/E that collectively support a higher fair value estimate despite a slightly higher discount rate. What’s in the News for Divi's Laboratories A board meeting is scheduled on August 1, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.Aggiornamento narrativa • Jul 08
DIVISLAB: Upcoming Board Decisions And Fair Value Assumptions Will Shape Balanced Outlook
Analysts have modestly raised their price target for Divi's Laboratories from ₹6,875 to approximately ₹7,059, citing updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E expectations. What's in the News Divi's Laboratories has scheduled a board meeting on May 23, 2026, at 10:15 Indian Standard Time to review audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Aggiornamento narrativa • Jun 24
DIVISLAB: Upcoming Board Meeting And Dividend Decision Will Support Bullish Outlook
Analysts have adjusted their fair value estimate for Divi's Laboratories slightly lower from ₹8,812.63 to ₹8,795.18, reflecting small tweaks to assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What’s in the News for Divi's Laboratories A board meeting is scheduled for May 23, 2026, at 10:15 Indian Standard Time to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Aggiornamento narrativa • Jun 09
DIVISLAB: Upcoming Board Meeting And Dividend Decision Will Support Bullish Outlook
Analysts have raised their fair value estimate for Divi's Laboratories from ₹8,620.23 to ₹8,812.63, reflecting updated assumptions for the discount rate, revenue growth, profit margins and future P/E expectations. What's in the News A board meeting is scheduled for May 23, 2026, at 10:15 IST to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Aggiornamento narrativa • May 26
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have lifted Divi's Laboratories price target from ₹5,133.17 to ₹5,333.98, citing updated assumptions on revenue growth, profit margins, and future P/E expectations. What's in the News A board meeting is scheduled for May 23, 2026, at 10:15 Indian Standard Time to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).Articolo di analisi • May 26
Divi's Laboratories Limited (NSE:DIVISLAB) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Divi's Laboratories Limited ( NSE:DIVISLAB ) last week reported its latest yearly results, which makes it a good time...Aggiornamento narrativa • May 04
DIVISLAB: Elevated Future P/E Will Remain A Key Overvaluation Risk
Analysts have trimmed their price target on Divi's Laboratories slightly from ₹5,140 to about ₹5,133, reflecting updated assumptions around discount rates, revenue growth, profit margin, and future P/E expectations. Valuation Changes Fair Value: Trimmed slightly from ₹5,140.00 to about ₹5,133.17 per share.Aggiornamento narrativa • Apr 20
DIVISLAB: Upcoming Board Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target for Divi's Laboratories slightly, with fair value now seen around ₹8,620 versus about ₹8,554 earlier, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled on Feb 11, 2026 to consider and approve unaudited standalone financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).Aggiornamento narrativa • Apr 05
DIVISLAB: Elevated Future P/E Will Persist Despite Unchanged Fair Value Estimate
Analysts have maintained Divi's Laboratories' fair value estimate at ₹5,140 per share, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together guide the latest price target narrative. What's in the News Board meeting scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Aggiornamento narrativa • Mar 22
DIVISLAB: Upcoming Board Review And Fair Value Update Signal Constructive Outlook
Analysts have made a small upward adjustment to the fair value estimate for Divi's Laboratories to around ₹6,875, reflecting slightly updated assumptions on the discount rate, revenue growth, profit margins and future P/E. What's in the News Board meeting scheduled on February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Aggiornamento narrativa • Mar 08
DIVISLAB: Rich Future P/E Will Persist Despite Softer Outlook After Results
Analysts have trimmed their price target on Divi's Laboratories from ₹5,290 to ₹5,140, reflecting updated assumptions around a slightly lower revenue growth outlook, a marginally higher profit margin, a modestly reduced future P/E multiple, and an adjusted discount rate. What's in the News A board meeting is scheduled for February 11, 2026 to review and approve unaudited standalone and consolidated financial results for the quarter ended December 31, 2025 (Key Developments).Aggiornamento narrativa • Feb 22
DIVISLAB: Upcoming Results Review Will Shape Balanced Long Term Outlook
Narrative Update on Divi's Laboratories The analyst price target for Divi's Laboratories has been adjusted slightly higher from about ₹6,823 to roughly ₹6,870, with analysts pointing to small refinements in assumptions around discount rate, revenue growth, profit margin and future P/E as the drivers of this change. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Aggiornamento narrativa • Feb 07
DIVISLAB: Upcoming Results Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target on Divi's Laboratories slightly to ₹6,823 from about ₹6,785, citing refreshed assumptions around discount rates, revenue growth, profit margin and future P/E that remain broadly in line with prior views. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Aggiornamento narrativa • Jan 24
DIVISLAB: Management Changes And Rich Future P/E Will Sustain Excessive Optimism
Analysts now cite slightly higher assumptions on growth, profitability and future P/E in their models for Divi's Laboratories, which feeds into an updated fair value estimate of ₹5,290, compared with the previous ₹5,035.89. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Aggiornamento narrativa • Jan 10
DIVISLAB: Upcoming Board Review And Management Changes Will Support Bullish Outlook
Analysts have raised their price target for Divi's Laboratories from ₹7,750 to about ₹8,554, citing updated assumptions related to revenue growth, profit margins and future P/E levels in their models. What's in the News Board meeting scheduled on Nov 07, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025 (company filing).Articolo di analisi • Dec 30
Earnings Not Telling The Story For Divi's Laboratories Limited (NSE:DIVISLAB)
Divi's Laboratories Limited's ( NSE:DIVISLAB ) price-to-earnings (or "P/E") ratio of 68.3x might make it look like a...Aggiornamento narrativa • Dec 25
DIVISLAB: Rising Profitability Expectations Will Mask Moderating Revenue And Justify Excessive Optimism
Analysts have raised their price target for Divi's Laboratories from ₹4,756 to ₹5,036, citing expectations of stronger profitability and a slightly richer future valuation multiple, despite moderating revenue growth assumptions. What's in the News Board meeting scheduled for November 7, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Aggiornamento narrativa • Dec 11
DIVISLAB: Upcoming Board Meeting And Leadership Review Will Shape Fair Outlook
Analysts have nudged their price target for Divi's Laboratories slightly higher, reflecting marginal improvements in discount rate assumptions and long term growth expectations that together support a fair value estimate of ₹6,785.10 per share. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 IST to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Articolo di analisi • Dec 09
Divi's Laboratories (NSE:DIVISLAB) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Aggiornamento narrativa • Nov 27
DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have raised their fair value estimate for Divi's Laboratories from ₹6,433 to ₹6,785, citing modest improvements in revenue growth and profit margin expectations. What's in the News A board meeting is scheduled for November 7, 2025, at 10:30 IST to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments).Articolo di analisi • Nov 15
Investors Shouldn't Be Too Comfortable With Divi's Laboratories' (NSE:DIVISLAB) Earnings
Despite posting some strong earnings, the market for Divi's Laboratories Limited's ( NSE:DIVISLAB ) stock hasn't moved...Articolo di analisi • Nov 11
Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Divi's Laboratories Limited ( NSE:DIVISLAB ) just released its latest interim results and things are looking bullish...Aggiornamento narrativa • Nov 08
DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have modestly increased their price target for Divi's Laboratories from ₹6,363 to ₹6,433, citing slight improvements in projected revenue growth and profit margins as the underlying factors. What's in the News Upcoming Board Meeting scheduled for November 7, 2025, at 10:30 AM IST.Aggiornamento narrativa • Sep 05
Custom Synthesis And Capacity Expansion Will Unlock Global Demand
With both the consensus price target and future P/E ratio for Divi's Laboratories remaining virtually unchanged, analysts signal stable valuation expectations, resulting in a steady fair value assessment at ₹6363. What's in the News Board meeting scheduled to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2025.
Nuova narrativa • Nov 10
Tactical Expansions And Innovation Could Offset Generic Pricing Pressures And Boost Profitability
Strategic investments in peptide synthesis and greenfield expansion enhance future revenue potential through capacity and product line growth.Rendimenti per gli azionisti
| DIVISLAB | IN Life Sciences | IN Mercato | |
|---|---|---|---|
| 7D | 2.4% | 1.2% | -1.4% |
| 1Y | 54.7% | 32.0% | -1.2% |
Ritorno vs Industria: DIVISLAB ha superato il Indian Life Sciences che ha restituito 32 % nell'ultimo anno.
Rendimento vs Mercato: DIVISLAB ha superato il mercato Indian che ha restituito -1.2 % nell'ultimo anno.
Volatilità dei prezzi
| DIVISLAB volatility | |
|---|---|
| DIVISLAB Average Weekly Movement | 3.8% |
| Life Sciences Industry Average Movement | 5.5% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in IN Market | 8.9% |
| 10% least volatile stocks in IN Market | 3.4% |
Prezzo delle azioni stabile: DIVISLAB non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Indian.
Volatilità nel tempo: La volatilità settimanale ( 4% ) di DIVISLAB è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1990 | 11,565 | Kiran Divi | www.divislabs.com |
Divi's Laboratories Limited si occupa della produzione e della vendita di principi attivi farmaceutici generici (API), prodotti intermedi e nutraceutici in India, Nord America, Asia, Europa e a livello internazionale. L'azienda si occupa anche di servizi di produzione a contratto di sintesi personalizzata di API e intermedi e fornisce una gamma di carotenoidi, come beta-carotene, astaxantina, licopene e cantaxantina, nonché altre forme finite, tra cui la luteina, e vitamine a industrie alimentari, integratori alimentari e produttori di mangimi. L'azienda esporta anche i suoi prodotti.
Divi's Laboratories Limited Riepilogo dei fondamenti
| DIVISLAB statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | ₹2.47t |
| Utili (TTM) | ₹29.25b |
| Ricavi(TTM) | ₹112.30b |
84.6x
Rapporto P/E22.0x
Rapporto P/SDIVISLAB è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| DIVISLAB Conto economico (TTM) | |
|---|---|
| Ricavi | ₹112.30b |
| Costo del fatturato | ₹43.53b |
| Profitto lordo | ₹68.77b |
| Altre spese | ₹39.52b |
| Utili | ₹29.25b |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 110.18 |
| Margine lordo | 61.24% |
| Margine di profitto netto | 26.05% |
| Rapporto debito/patrimonio netto | 0.04% |
Come si è comportato DIVISLAB nel lungo periodo?
Vedi performance storica e confrontoDividendi
0.3%
Rendimento attuale del dividendo31%
Rapporto di remunerazioneAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/11 11:02 |
| Prezzo dell'azione a fine giornata | 2026/09/11 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Divi's Laboratories Limited è coperta da 54 analisti. 29 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| Kumar Saumya Singh | Ambit Capital |